Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 STAT3: too much may be worse than not enough!

Literature DB >> 25614633

STAT3: too much may be worse than not enough!

Elie Haddad¹.
1. UNIVERSITY OF MONTREAL.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2015 PMID： 25614633 DOI： 10.1182/blood-2014-11-610592

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

Review 1. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Authors: Marcin Kortylewski; Dayson Moreira
Journal: Cancer Immunol Immunother Date: 2017-02-18 Impact factor: 6.968

Review 2. Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.

Authors: Luigi D Notarangelo; Thomas A Fleisher
Journal: J Allergy Clin Immunol Date: 2017-03 Impact factor: 10.793

Review 3. Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies.

Authors: Ottavia Maria Delmonte; Luigi Daniele Notarangelo
Journal: Med Princ Pract Date: 2019-10-10 Impact factor: 1.927

4. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

Authors: Pilar Blanco Lobo; Paloma Guisado-Hernández; Isabel Villaoslada; Beatriz de Felipe; Carmen Carreras; Hector Rodriguez; Begoña Carazo-Gallego; Ana Méndez-Echevarria; José Manuel Lucena; Pilar Ortiz Aljaro; María José Castro; José Francisco Noguera-Uclés; Joshua D Milner; Katelyn McCann; Ofer Zimmerman; Alexandra F Freeman; Michail S Lionakis; Steven M Holland; Olaf Neth; Peter Olbrich
Journal: J Clin Immunol Date: 2022-05-04 Impact factor: 8.542

STAT3: too much may be worse than not enough!

Review 1. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Review 2. Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.

Review 3. Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies.

4. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

Review 5. Signal transducer and activator of transcription 3: a year in review.

6. [Immune dysregulation syndrome caused by STAT3 gene mutation: a complicated case study].

Review 7. STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity.

8. Mapping of Signaling Pathways Linked to sIgAD Reveals Impaired IL-21 Driven STAT3 B-Cell Activation.

Review 9. Inborn Errors of Immunity With Immune Dysregulation: From Bench to Bedside.

Review 10. Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.